Jacqueline Shan, Ph.D., D.Sc
President and Chief Scientific Officer
Afexa Life Sciences Inc. (Formally CV Technologies Inc)
Edmonton, Canada
Presentation to MaRS Discovery, May 5th, 2009

• Chronic diseases such as cardiovascular diseases,
obesity and diabetes will account for 70% of all
death worldwide by 2020-WHO
• In 2001, chronic diseases contributed 60% of all
death worldwide and 46% of the total burden of
diseases
• Increases in disease incidence lead to overall
increases in the cost of healthcare
• Our current “health–care system” is a diseases-care
system. 75% was spent on treating chronic diseases
that are preventable or even reversible by changing
diet and lifestyle
2

• Nature: a great source of Medicine
• Shorter Discovery Phase
• Mature Pharmaceutical Development Models for
advanced preclinical and Clinical phases
• Better Safety Profile
• Prevention and Intervention
• Sustainable and Affordable
• Canadian and International Regulatory Framework:
Canada, US and Asia Safe and Effective
• Green and environmental friendly
3

To transform people's lives to be healthier and
happier by focusing on prevention and recovery
through the use of evidence-based naturally-
derived health products.
4

• Spin off from U of A in 1992
• Direction of innovation: Natural Health Product (NHP)
Standardization Technology Immunotherapy for
infectious diseases, Cancer management, Metabolic
Syndrome management, Neuropsychological
management
• Extensive patent folio, Proprietary Technology
Platform- ChemBioPrint Technology
• Successful commercialization with lead product
COLD-fX since 2003
5

• Economic burden of Colds and Flu - $4-6 billion
• Lack of conventional and effective drugs and
vaccines
• Unnecessary and ineffective physician visits
• Loss of work days and productivity
6

7

• More than a decade of research
• 10 clinical trials
• Published in 9 major peer-reviewed medical journals
• Safe and effective
• International Olympic Committee (IOC) protocol
testing demonstrated that COLD-FX did not contain
or induce any banned substances, unlike some cold
medicines
• Health Canada NPN approval
8

9

10

COLD-FX Net Sales ($ CDN millions)
*Sales includes all Afexa products, year-end September 30
11

COLD-fX #1 selling brand for all cold remedies
& natural supplements*
* Source: Nielsen Brand Overview, National All Channels total Cold Remedies (including
antihistamines) and Natural supplements for 52 weeks ending December 22, 2007
12

• Today COLD-fX 60’s is the #1 selling cold remedy in Canada
• The COLD-fX brand is essentially tied for first place among all
Cough/Cold brands with 3 skus
Brand
Brand Rank Total $ # of SKU’s
TYLENOL 1 $38.0 million 47
COLD-fX™ 2 $37.9 million 3
ADVIL 3 $30.6 million 16
NYQUIL/DAYQUIL 4 $18.0 million 16
NEO CITRAN 5 $13.7 million 28
CONTAC 6 $7.9 million 35
BENYLIN 7 $7.6 million 14
SUDAFED 8 $6.9 million 18
DIMETAPP 9 $6.8 million 13
SINUTAB 10 $5.8 million 14
13

Pharmacy Post magazine’s
#1 pharmacist recommended
natural cold remedy
14

• First evidence based and safe NHP for cold and flu
prevention and treatment-a better choice over
traditional drugs and added benefit to flu vaccine
• Consumer acceptance prove Canadians willing to
proactively prevent and manage colds and flu
• Positive social and economic outcome: Prevention,
improving quality of life, reducing possible doctor visits
and unnecessary prescriptions, reduce work day loss
and improve productivity
15

• Going forward, the market opportunity isn’t
necessarily to steal share, but rather to be
complimentary to traditional “treatment” remedies
• Expansion of preventative solution options as
potential source for future market growth
16

• U.S. National Cancer Institute (NCI)- WORLD’S TOP
CANCER RESEARCH BODY SPONSORS LANDMARK
COLD-FX® TRIAL
The landmark sponsored trial involving chronic lymphocyte
leukemia patients – the first time the natural medicine will
be part of a clinical study associated with cancer.
17

• Committing to Our Vision
• Committing to Science and Quality
• Committing to Discipline, High Integrity and Best
Business Practice
• Adapting to Change and Move Fast
• Thinking Big but One-step at a Time
• Being an Innovative Trail Blazer and Not Accepting
Failure
• Valuing Team Work and Respecting and Helping Our
Teammates
• Having a “Can-do” Attitude and Being Passionate
about Our Cause
18

Afexa products are an environmentally
responsible choice for consumers…
All natural products
Scientifically developed and
rigorously produced
Safe for the human body
Devoid of synthetic chemicals
that degrade the environment
19

• Increased Public Awareness and Demands
• >10,000 Retail Establishments
• $2.5 billion retail sales in NHPs, $3 billion in
Functional foods and growing
• International Opportunities
20

• Could create new emerging preventative,
evidence-based NHP/Functional food industry
for disease prevention and health promotion
• Innovative products and technology could
reshape and improve healthcare landscape
21

• Regulatory uncertainty on pathways and health
claims
• Management expertise in commercialization
• Research & innovation capacity and capability
(Funding, validated methods, scale-up facilities)
• Access to technology and ownership of IPs
• Under-informed health care professionals and
consumers on diet-health relationship and
potential NHPs’ contribution to health
• Global presence and competitiveness
22

• Stream-lining and improving regulatory framework for
NHPs and functional foods
• Integrating Evidence-based NHPs and Functional
Foods into health care and health management
• Emphasizing and integrating prevention into
healthcare policies
• Investing and building an integrated innovation and
research infrastructure including Agi-Food, Health and
Innovation
• Investing and encouraging entrepreneurship and
commercialization
23

• Helping streamline regulatory framework and policies
• Investing and encouraging research and innovation
• Investing and encouraging commercialization: e.g.,
clinical research and validation; production scale-up
• Investing and encouraging training skilled scientific
and business professionals
• Facilitating assess to research and technologies
• IP policy to allow industry owning IP or the right of IP
24

• Cross Sector Collaboration
• Industry Focusing on Accessing and Utilizing the
Innovation and Technology
• Leveraging the Resources, Compliment the Strengths
• Building a Viable NPH and Functional Food Industry
and Research Community Together
25

26